Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis
about
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials.Vandetanib for the treatment of metastatic medullary thyroid cancerEfficacy and tolerability of pharmacotherapy options for the treatment of medullary thyroid cancer.Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).Update on the molecular diagnosis and targeted therapy of thyroid cancer.Vandetanib as a potential treatment for breast cancer.Novel therapies for thyroid cancer.Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy.Cancer chemotherapy and cardiac arrhythmias: a review.Sorafenib for the treatment of thyroid cancer: an updated review.Receptor tyrosine kinase inhibitors: Are they real tumor killers?Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management.The safety of vandetanib for the treatment of thyroid cancer.Arrhythmic complications of tyrosine kinase inhibitors.Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib.Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors.ACTH-secreting medullary thyroid cancer: a case series.Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective.Electrophysiological mechanisms of vandetanib-induced cardiotoxicity: Comparison of action potentials in rabbit Purkinje fibers and pluripotent stem cell-derived cardiomyocytes.
P2860
Q27692050-17B7A3E6-F511-4A70-9A35-10FBB874BAB1Q30847302-C29CAFF0-3BEB-4C1A-9BD2-1BC4D078C8D9Q36729895-FB32FB2B-0E43-467E-BF5C-45411B38D9BCQ38020834-28F76F76-B8EA-4978-BDB5-D595F3219FCDQ38058321-F4DCF6D0-39EB-4319-9274-FE7154F678DBQ38101883-6C60E495-977D-4D6E-B228-27FE7D040CA1Q38208701-0BB3FFCC-8A11-47FD-8456-70072C45DFBBQ38236623-E90A169F-2EFD-4781-880C-4FD8C729459AQ38260495-E8FD7069-0618-449A-BF4E-22072F926F00Q38286128-38C5E3BC-719E-4021-9245-22333D7E01ADQ38313870-3DB60E97-7C83-4021-A5CE-973148AFC472Q38326036-28859A3F-9ECF-419A-81F9-FB1A4339438BQ38365290-76D8F1CA-B811-4871-A521-F28960B3A29CQ38625034-EDB656AD-A984-47FD-8F96-EE53CE7CB069Q38744149-2EA6B97C-75F4-4F34-B1FB-EE8A802E1383Q38864998-13D63913-9274-4A24-8EA2-B745F429BDADQ38978097-25678136-F48A-4A94-BC6F-79E809603F69Q41263498-B19A04AE-C922-448B-A962-C49243CF3EA0Q41341776-2F8728D4-EC2E-493E-BA5A-D631101475C8Q42014281-4A4B689B-C0C9-4ACD-814A-F31EC0679E74Q51760757-E0CA479F-1C90-46E5-BE52-69B1BCEB893FQ54116941-D89EDB43-C1B8-4069-B8AB-39F07FF53898
P2860
Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Incidence and risk of QTc inte ...... matic review and meta-analysis
@ast
Incidence and risk of QTc inte ...... matic review and meta-analysis
@en
Incidence and risk of QTc inte ...... matic review and meta-analysis
@nl
type
label
Incidence and risk of QTc inte ...... matic review and meta-analysis
@ast
Incidence and risk of QTc inte ...... matic review and meta-analysis
@en
Incidence and risk of QTc inte ...... matic review and meta-analysis
@nl
prefLabel
Incidence and risk of QTc inte ...... matic review and meta-analysis
@ast
Incidence and risk of QTc inte ...... matic review and meta-analysis
@en
Incidence and risk of QTc inte ...... matic review and meta-analysis
@nl
P2093
P2860
P31
P921
P1433
P1476
Incidence and risk of QTc inte ...... matic review and meta-analysis
@en
P2093
Caicui Ding
Enming Kang
Shunquan Wu
P2860
P304
P356
10.1371/JOURNAL.PONE.0030353
P407
P50
P5008
P577
2012-02-17T00:00:00Z